Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.
Identifieur interne : 000D55 ( Main/Exploration ); précédent : 000D54; suivant : 000D56Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.
Auteurs : Emre Kara [Turquie] ; Kutay Demirkan [Turquie] ; Serhat Unal [Turquie]Source :
- International journal of antimicrobial agents [ 1872-7913 ] ; 2020.
Descripteurs français
- KwdFr :
- Antiviraux (pharmacocinétique), Antiviraux (pharmacologie), Antiviraux (sang), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (immunologie), Calcul des posologies (MeSH), Calendrier d'administration des médicaments (MeSH), Guides de bonnes pratiques cliniques comme sujet (MeSH), Humains (MeSH), Hydroxychloroquine (pharmacocinétique), Hydroxychloroquine (pharmacologie), Hydroxychloroquine (sang), Indice de gravité de la maladie (MeSH), Infections à coronavirus (complications), Infections à coronavirus (sang), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Maladies cardiovasculaires (complications), Maladies cardiovasculaires (sang), Maladies cardiovasculaires (traitement médicamenteux), Maladies cardiovasculaires (virologie), Pandémies (MeSH), Pneumopathie virale (complications), Pneumopathie virale (sang), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Résultat thérapeutique (MeSH).
- MESH :
- effets des médicaments et des substances chimiques : Betacoronavirus.
- immunologie : Betacoronavirus.
- pharmacocinétique : Antiviraux, Hydroxychloroquine, Infections à coronavirus, Maladies cardiovasculaires, Pneumopathie virale.
- pharmacologie : Antiviraux, Hydroxychloroquine.
- sang : Antiviraux, Hydroxychloroquine, Infections à coronavirus, Maladies cardiovasculaires, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus, Maladies cardiovasculaires, Pneumopathie virale.
- virologie : Infections à coronavirus, Maladies cardiovasculaires, Pneumopathie virale.
- Calcul des posologies, Calendrier d'administration des médicaments, Guides de bonnes pratiques cliniques comme sujet, Humains, Indice de gravité de la maladie, Pandémies, Résultat thérapeutique.
English descriptors
- KwdEn :
- Antiviral Agents (blood), Antiviral Agents (pharmacokinetics), Antiviral Agents (pharmacology), Betacoronavirus (drug effects), Betacoronavirus (immunology), COVID-19 (MeSH), Cardiovascular Diseases (blood), Cardiovascular Diseases (complications), Cardiovascular Diseases (drug therapy), Cardiovascular Diseases (virology), Coronavirus Infections (blood), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (virology), Drug Administration Schedule (MeSH), Drug Dosage Calculations (MeSH), Humans (MeSH), Hydroxychloroquine (blood), Hydroxychloroquine (pharmacokinetics), Hydroxychloroquine (pharmacology), Pandemics (MeSH), Pneumonia, Viral (blood), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Pneumonia, Viral (virology), Practice Guidelines as Topic (MeSH), SARS-CoV-2 (MeSH), Severity of Illness Index (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , blood : Antiviral Agents, Hydroxychloroquine.
- chemical , pharmacokinetics : Antiviral Agents, Hydroxychloroquine.
- chemical , pharmacology : Antiviral Agents, Hydroxychloroquine.
- blood : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- complications : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- drug effects : Betacoronavirus.
- drug therapy : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- immunology : Betacoronavirus.
- virology : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Drug Administration Schedule, Drug Dosage Calculations, Humans, Pandemics, Practice Guidelines as Topic, SARS-CoV-2, Severity of Illness Index, Treatment Outcome.
DOI: 10.1016/j.ijantimicag.2020.106123
PubMed: 32738307
PubMed Central: PMC7390798
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.</title><author><name sortKey="Kara, Emre" sort="Kara, Emre" uniqKey="Kara E" first="Emre" last="Kara">Emre Kara</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey. Electronic address: emrekara@hacettepe.edu.tr.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name sortKey="Demirkan, Kutay" sort="Demirkan, Kutay" uniqKey="Demirkan K" first="Kutay" last="Demirkan">Kutay Demirkan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name sortKey="Unal, Serhat" sort="Unal, Serhat" uniqKey="Unal S" first="Serhat" last="Unal">Serhat Unal</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32738307</idno><idno type="pmid">32738307</idno><idno type="doi">10.1016/j.ijantimicag.2020.106123</idno><idno type="pmc">PMC7390798</idno><idno type="wicri:Area/Main/Corpus">001019</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001019</idno><idno type="wicri:Area/Main/Curation">001019</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001019</idno><idno type="wicri:Area/Main/Exploration">001019</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.</title><author><name sortKey="Kara, Emre" sort="Kara, Emre" uniqKey="Kara E" first="Emre" last="Kara">Emre Kara</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey. Electronic address: emrekara@hacettepe.edu.tr.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name sortKey="Demirkan, Kutay" sort="Demirkan, Kutay" uniqKey="Demirkan K" first="Kutay" last="Demirkan">Kutay Demirkan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name sortKey="Unal, Serhat" sort="Unal, Serhat" uniqKey="Unal S" first="Serhat" last="Unal">Serhat Unal</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author></analytic><series><title level="j">International journal of antimicrobial agents</title><idno type="eISSN">1872-7913</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (blood)</term><term>Antiviral Agents (pharmacokinetics)</term><term>Antiviral Agents (pharmacology)</term><term>Betacoronavirus (drug effects)</term><term>Betacoronavirus (immunology)</term><term>COVID-19 (MeSH)</term><term>Cardiovascular Diseases (blood)</term><term>Cardiovascular Diseases (complications)</term><term>Cardiovascular Diseases (drug therapy)</term><term>Cardiovascular Diseases (virology)</term><term>Coronavirus Infections (blood)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (virology)</term><term>Drug Administration Schedule (MeSH)</term><term>Drug Dosage Calculations (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (blood)</term><term>Hydroxychloroquine (pharmacokinetics)</term><term>Hydroxychloroquine (pharmacology)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (blood)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (virology)</term><term>Practice Guidelines as Topic (MeSH)</term><term>SARS-CoV-2 (MeSH)</term><term>Severity of Illness Index (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (pharmacocinétique)</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (sang)</term><term>Betacoronavirus (effets des médicaments et des substances chimiques)</term><term>Betacoronavirus (immunologie)</term><term>Calcul des posologies (MeSH)</term><term>Calendrier d'administration des médicaments (MeSH)</term><term>Guides de bonnes pratiques cliniques comme sujet (MeSH)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (pharmacocinétique)</term><term>Hydroxychloroquine (pharmacologie)</term><term>Hydroxychloroquine (sang)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Infections à coronavirus (complications)</term><term>Infections à coronavirus (sang)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (virologie)</term><term>Maladies cardiovasculaires (complications)</term><term>Maladies cardiovasculaires (sang)</term><term>Maladies cardiovasculaires (traitement médicamenteux)</term><term>Maladies cardiovasculaires (virologie)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Pneumopathie virale (sang)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (virologie)</term><term>Résultat thérapeutique (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Cardiovascular Diseases</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Cardiovascular Diseases</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cardiovascular Diseases</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Antiviraux</term><term>Hydroxychloroquine</term><term>Infections à coronavirus</term><term>Maladies cardiovasculaires</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Antiviraux</term><term>Hydroxychloroquine</term><term>Infections à coronavirus</term><term>Maladies cardiovasculaires</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Maladies cardiovasculaires</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Maladies cardiovasculaires</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Cardiovascular Diseases</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Drug Administration Schedule</term><term>Drug Dosage Calculations</term><term>Humans</term><term>Pandemics</term><term>Practice Guidelines as Topic</term><term>SARS-CoV-2</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Calcul des posologies</term><term>Calendrier d'administration des médicaments</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Indice de gravité de la maladie</term><term>Pandémies</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32738307</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7913</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of antimicrobial agents</Title><ISOAbbreviation>Int J Antimicrob Agents</ISOAbbreviation></Journal><ArticleTitle>Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.</ArticleTitle><Pagination><MedlinePgn>106123</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0924-8579(20)30306-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijantimicag.2020.106123</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kara</LastName><ForeName>Emre</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey. Electronic address: emrekara@hacettepe.edu.tr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demirkan</LastName><ForeName>Kutay</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unal</LastName><ForeName>Serhat</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Antimicrob Agents</MedlineTA><NlmUniqueID>9111860</NlmUniqueID><ISSNLinking>0924-8579</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054796" MajorTopicYN="N">Drug Dosage Calculations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of Competing Interest None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>07</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32738307</ArticleId><ArticleId IdType="pii">S0924-8579(20)30306-X</ArticleId><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106123</ArticleId><ArticleId IdType="pmc">PMC7390798</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rheumatol Ther. 2015 Dec;2(2):183-195</Citation><ArticleIdList><ArticleId IdType="pubmed">27747530</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2020 Aug;108(2):253-263</Citation><ArticleIdList><ArticleId IdType="pubmed">32285930</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2020 Oct;108(4):766-769</Citation><ArticleIdList><ArticleId IdType="pubmed">32344449</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Drug Monit. 2003 Dec;25(6):671-81</Citation><ArticleIdList><ArticleId IdType="pubmed">14639053</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Turquie</li></country></list><tree><country name="Turquie"><noRegion><name sortKey="Kara, Emre" sort="Kara, Emre" uniqKey="Kara E" first="Emre" last="Kara">Emre Kara</name></noRegion><name sortKey="Demirkan, Kutay" sort="Demirkan, Kutay" uniqKey="Demirkan K" first="Kutay" last="Demirkan">Kutay Demirkan</name><name sortKey="Unal, Serhat" sort="Unal, Serhat" uniqKey="Unal S" first="Serhat" last="Unal">Serhat Unal</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32738307
|texte= Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32738307" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |